Compare Recursion Pharmaceuticals Inc (RXRX) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Xcel Energy Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while Xcel Energy Inc trades at $76.33 (market cap $48.02B). The key difference: Xcel Energy Inc is far larger — about 25.8× Recursion Pharmaceuticals Inc's market cap, and Xcel Energy Inc pays a 3.08% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | XEL | |
|---|---|---|
Market Cap | $1.86B | $48.02B |
Sector | Health | Utilities |
52-Week High | $6.79 | $83.91 |
52-Week Low | $2.84 | $72.05 |
Enterprise Value | $1.38B | $86.33B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
XEL trades at $76.88, up 1.53% on the day, with a bearish technical signal but strong analyst consensus. Recent Q2 2026 earnings beat estimates at $0.93 per share. The company maintains solid profitability with a 15.28% net income margin and is executing a $70B+ capital investment plan through 2030 to drive growth. Dividend payments remain consistent at $0.59 quarterly.
Outlook is positive with a $92 consensus price target, though risks include high capital expenditures, regulatory scrutiny from wildfire lawsuits, and rising interest rates. The stock offers stable income and growth potential but faces execution and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
